Dopaminergic Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Dopaminergic neurodegeneration describes the progressive loss and dysfunction of [dopaminergic neurons[/cell-types/[dopaminergic-neurons[/cell-types/[dopaminergic-neurons[/cell-types/[dopaminergic-neurons--TEMP--/cell-types)--FIX--[1], especially in the [substantia nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra--TEMP--/brain-regions)--FIX--[2], that drives core motor and non-motor features of [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--[3]. Neuronal
injury reflects the combined burden of [mitochondrial dysfunction[/mechanisms/[mitochondrial-dysfunction[/mechanisms/[mitochondrial-dysfunction[/mechanisms/[mitochondrial-dysfunction--TEMP--/mechanisms)--FIX--[4],
[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX-- aggregation[5], oxidative stress, calcium dysregulation, and chronic
[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX--[1]. These converging processes create a selective
vulnerability state in nigrostriatal circuits, making dopaminergic neuron preservation a central goal for disease-modifying therapeutics.
The study of Dopaminergic Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [/diseases/parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--
- [/mechanisms/alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein--TEMP--/mechanisms)--FIX--
- [/mechanisms/app-processing[/mechanisms/[app-processing[/mechanisms/[app-processing[/mechanisms/[app-processing--TEMP--/mechanisms)--FIX--
- [/mechanisms/amyloid-aggregation[/mechanisms/[amyloid-aggregation[/mechanisms/[amyloid-aggregation[/mechanisms/[amyloid-aggregation--TEMP--/mechanisms)--FIX--
- [/mechanisms/microglia-neuroinflammation[/mechanisms/[microglia-neuroinflammation[/mechanisms/[microglia-neuroinflammation[/mechanisms/[microglia-neuroinflammation--TEMP--/mechanisms)--FIX--
- [Surmeier, D.J., Obeso, J.A., Halliday, G.M. (2017]. Selective neuronal vulnerability in Parkinson disease. Nature Reviews Neuroscience, 18(2), 101–113. DOI
- [Poewe, W., Seppi, K., Tanner, C.M., et al. (2017]. Parkinson disease. Nature Reviews Disease Primers, 3, 17013. DOI
- [Bloem, B.R., Okun, M.S., Klein, C. (2021]. Parkinson's Disease. The Lancet, 397(10291), 2284–2303. DOI
- [Devi, L., Raghavendran, V., Prabhu, B.M., et al. (2008]. Mitochondrial import and accumulation of α-synuclein impair Complex I in human dopaminergic neuronal cultures and Parkinson disease brain. Journal of Biological Chemistry, 283(14), 9089–9100. DOI
- [Ludtmann, M.H.R., Angelova, P.R., Horrocks, M.H., et al. (2018]. α-Synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson's Disease. Nature Communications, 9(1), 2293. DOI
- [Outeiro, T.F., Klucken, J., Bercury, K., et al. (2009]. Dopamine-induced conformational changes in [alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein--TEMP--/mechanisms)--FIX--. PLoS ONE, 4(9), e6906. DOI
- [Zimprich, A., Biskup, S., Leitner, P., et al. (2004]. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. [Neuron[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, 44(4), 601–607. DOI
- [Sidransky, E., Nalls, M.A., Aasly, J.O., et al. (2009]. Multicenter analysis of glucocerebrosidase mutations in Parkinson's Disease. New England Journal of Medicine, 361(17), 1651–1661. DOI
- [Gonzalez-Rodriguez, P., Zampese, E., Surmeier, D.J. (2020]. Selective neuronal vulnerability in Parkinson's Disease. Progress in Brain Research, 252, 61–89. DOI
- [Blandini, F., Armentero, M.T. (2012]. Dopamine receptor agonists for Parkinson's Disease. Expert Opinion on Investigational Drugs, 21(6), 780–818. DOI
- [Halliday, G.M., McCann, H. (2010]. The progression of pathology in Parkinson's Disease. Annals of the New York Academy of Sciences, 1184(1), 188–195. DOI
- [Rossi, M., et al. (2025]. Classification and genotype-phenotype relationships of GBA1 variants: MDSGene systematic review. Movement Disorders, 40(2), 236–249. DOI
- [Tolosa, E., Garrido, A., Scholz, S.W., Poewe, W. (2021]. Challenges in the diagnosis of Parkinson's Disease. The Lancet Neurology, 20(5), 385–397. DOI## See Also
- [Tolosa, E., Garrido, A., Scholz, S.W., Poewe, W. (2021]. Challenges in the diagnosis of Parkinson's Disease. The Lancet Neurology, 20(5), 385–397. DOI## External Links
-
-
-
- Marogianni C et al., Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disease (2020)
- Kalinderi K et al., GLP-1 Receptor Agonists: A New Treatment in Parkinson's Disease (2024)
- Cramb KML et al., Impaired dopamine release in Parkinson's Disease (2023)
- Cacabelos R, Parkinson's Disease: From Pathogenesis to Pharmacogenomics (2017)
- Miyazaki I, Asanuma M, Neuron-Astrocyte Interactions in Parkinson's Disease (2020)
- Zhou ZD et al., Role of dopamine in the pathophysiology of Parkinson's Disease (2023)
🟡 Moderate Confidence
| Dimension |
Score |
| Supporting Studies |
23 references |
| Replication |
33% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 49%